Day One Biopharmaceuticals' (DAWN) "Outperform" Rating Reite

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a report issued on Wednesday, RTT News reports. They currently have a $33.00 price objective on the stock. Wedbush’s price target indicates a potential upside of 114.98% from the stock’s current price. A number of […]

Related Keywords

China , Samuelc Blackman , Piper Sandler , Jeremy Bender , Exchange Traded Concepts , China Universal Asset Management Co , Nasdaq , Quintet Private Bank Europe , Needham Company , Jpmorgan Chase Co , Day One Biopharmaceuticals Inc , Securities Exchange Commission , Quest Partners , Day One Biopharmaceuticals , Get Free Report , One Biopharmaceuticals , Exchange Commission , Universal Asset Management , Traded Concepts , Day One Biopharmaceuticals Daily ,